StockTake: Lumos submits CLIA waiver application to FDA for FebriDx

Stockhead’s Tylah Tully looks at news from Lumos Diagnostics (ASX:LDX), who has submitted its application to the FDA for CLIA waiver approval for FebriDx, a rapid point-of-care diagnostic test to determine the difference between bacterial and non-bacterial acute respiratory infections.

In the CLIA study, FebriDx showed it was accurate and reliable for trained professionals and untrained users alike. 

The diagnostic tool delivered accurate results 99.1% of the time for bacterial infections and 98.4% of the time for patients without bacterial infections.

Watch the video to learn more.

This video was developed in collaboration with Lumos Diagnostics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.